Altimmune, INC Form 4 insider transactions

Gregory L Weaver, Chief Financial Officer of Altimmune, Inc., received 1,753 shares of common stock on July 31, 2026.

M Scot Roberts, Chief Scientific Officer of Altimmune, Inc., received 875 shares of common stock on July 31, 2026.

Director Teri Lawver was granted 48,800 stock options in Altimmune, Inc. as part of the company's non-employee director compensation policy.

Altimmune, Inc. director Catherine A. Sohn received 48,800 stock options as part of the company's standard non-employee director compensation policy.

Altimmune, Inc. director Diane Jorkasky has been granted 48,800 stock options as part of the company's standard non-employee director compensation policy.

Director Klaus Schafer was granted 48,800 stock options in Altimmune, Inc. as part of the company's non-employee director compensation policy.

Director Wayne Pisano was granted 48,800 stock options in Altimmune, Inc. as part of the company's non-employee director compensation policy.

Director Philip Hodges was granted 48,800 stock options in Altimmune, Inc. as part of the company's non-employee director compensation policy.

Director John Gill was granted 48,800 stock options in Altimmune, Inc. as part of the company's non-employee director compensation policy.

Altimmune, Inc.'s President and CEO, Jerome Benedict Durso, acquired 15,000 shares of common stock at $3.14 per share through a pre-arranged plan.

Altimmune's Chief Scientific Officer, M Scot Roberts, was granted 222,670 stock options and 95,430 restricted stock units.

Altimmune's Chief Financial Officer, Gregory L. Weaver, received grants of 259,000 stock options and 111,000 Restricted Stock Units.

Altimmune's Chief Scientific Officer, M. Scot Roberts, increased his beneficial ownership of common stock through the vesting of Restricted Stock Units and participation in the Employee Stock Purchase Plan.

Altimmune Director Vipin Garg reported recent acquisitions and dispositions of company common stock, including RSU vesting and ESPP purchases.

Altimmune's Chief Business Officer, Raymond M. Jordt, acquired 4,571 shares of common stock through the company's Employee Stock Purchase Plan.

Altimmune's Chief Business Officer, Raymond M. Jordt, acquired 15,850 shares through RSU vesting and simultaneously disposed of 4,229 shares to cover tax obligations.

Altimmune Director Vipin Garg reported the vesting of 41,200 Restricted Stock Units and the subsequent sale of 17,898 shares to cover tax obligations.

Altimmune's Chief Scientific Officer, M. Scot Roberts, reported the exercise of Restricted Stock Units and a subsequent sale of shares to cover tax obligations.

Altimmune's Chief Business Officer, Raymond M. Jordt, acquired 14,600 shares through RSU vesting and sold 3,855 shares to cover tax obligations.

Altimmune Director Vipin K Garg reported the vesting of 42,050 restricted stock units and the sale of 17,984 shares to cover associated taxes.

Altimmune's Chief Scientific Officer, M Scot Roberts, exercised 14,600 Restricted Stock Units and subsequently sold 4,373 shares to cover tax obligations.

Altimmune Director Wayne Pisano acquired 5,000 shares of common stock at $4.082 per share, increasing his direct beneficial ownership to 13,498 shares.

Altimmune's Chief Business Officer, Raymond M. Jordt, converted Restricted Stock Units into common stock and sold a portion to cover tax obligations.

Altimmune Director Catherine A. Sohn purchased 500 shares of common stock, increasing her direct beneficial ownership to 1,500 shares.

Altimmune Director Diane Jorkasky acquired 527 shares of common stock at $3.80 per share, indicating potential future confidence.

Altimmune, Inc. Director John Gill acquired 12,500 shares of common stock at $4.10 per share, signaling insider confidence.

Altimmune, Inc. Director Jerome Benedict Durso plans to purchase 12,500 shares of common stock on December 22, 2025, at a weighted average price of $4.1255.

Altimmune, Inc. announced the appointment of Jerome Benedict Durso as President and CEO effective January 1, 2026, accompanied by substantial equity awards.

Altimmune's CFO, Gregory L. Weaver, reported the vesting of 18,750 Restricted Stock Units and a subsequent sale of 5,672 shares to cover tax obligations.

Altimmune's Chief Financial Officer, Gregory L. Weaver, was granted 166,800 stock options and 57,900 Restricted Stock Units, vesting over four years.